JP2005533830A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533830A5
JP2005533830A5 JP2004519059A JP2004519059A JP2005533830A5 JP 2005533830 A5 JP2005533830 A5 JP 2005533830A5 JP 2004519059 A JP2004519059 A JP 2004519059A JP 2004519059 A JP2004519059 A JP 2004519059A JP 2005533830 A5 JP2005533830 A5 JP 2005533830A5
Authority
JP
Japan
Prior art keywords
cox
inhibitor
pharmaceutical composition
thromboxane
package
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004519059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533830A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/002633 external-priority patent/WO2004004776A1/en
Publication of JP2005533830A publication Critical patent/JP2005533830A/ja
Publication of JP2005533830A5 publication Critical patent/JP2005533830A5/ja
Withdrawn legal-status Critical Current

Links

JP2004519059A 2002-07-09 2003-07-03 トロンボキサンa2受容体アンタゴニストおよびcox−2阻害剤の薬剤の組み合わせ Withdrawn JP2005533830A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39426802P 2002-07-09 2002-07-09
PCT/IB2003/002633 WO2004004776A1 (en) 2002-07-09 2003-07-03 Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor

Publications (2)

Publication Number Publication Date
JP2005533830A JP2005533830A (ja) 2005-11-10
JP2005533830A5 true JP2005533830A5 (enExample) 2006-08-17

Family

ID=30115701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004519059A Withdrawn JP2005533830A (ja) 2002-07-09 2003-07-03 トロンボキサンa2受容体アンタゴニストおよびcox−2阻害剤の薬剤の組み合わせ

Country Status (7)

Country Link
US (2) US20050020657A1 (enExample)
EP (1) EP1519753A1 (enExample)
JP (1) JP2005533830A (enExample)
CN (1) CN1665538A (enExample)
AU (1) AU2003244913A1 (enExample)
CA (1) CA2491848A1 (enExample)
WO (1) WO2004004776A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1660076A1 (en) * 2003-08-07 2006-05-31 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20060217431A1 (en) * 2005-03-23 2006-09-28 Boehringer Ingelheim International Gmbh Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor
US20070037797A1 (en) * 2005-08-15 2007-02-15 Hellstrom Harold R Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
CA2688319A1 (en) * 2007-05-03 2008-11-13 Portola Pharmaceuticals, Inc. Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists
US8188267B2 (en) * 2008-02-13 2012-05-29 Eastman Chemical Company Treatment of cellulose esters
WO2011046853A1 (en) 2009-10-12 2011-04-21 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
MX2012010077A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Vetmed Uso de meloxicam para el tratamiento a largo plazo de trastornos musculoesqueleticos en gatos.
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
AU2015258805B2 (en) * 2014-05-16 2018-05-10 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
AU2016285566A1 (en) * 2015-06-30 2017-12-14 Cumberland Pharmaceuticals, Inc. Thromboxane receptor antagonists in AERD/asthma
CN106188245A (zh) * 2016-08-30 2016-12-07 苏州普罗达生物科技有限公司 血栓烷a2抑制剂多肽及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK471479A (da) * 1978-12-13 1980-06-14 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
GB9220137D0 (en) * 1992-09-23 1992-11-04 Pfizer Ltd Therapeutic agents
JPH0753505A (ja) * 1992-10-01 1995-02-28 Hokuriku Seiyaku Co Ltd ベンゼンスルホンアミド誘導体及びその用途
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
JP2004521856A (ja) * 2000-05-15 2004-07-22 メルク フロスト カナダ アンド カンパニー Cox−2選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物
WO2003035063A1 (en) * 2001-10-25 2003-05-01 Dinesh Shantilal Patel Novel preparation of selective cyclooxygenase ii inhibitors
WO2004002409A2 (en) * 2002-06-27 2004-01-08 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use

Similar Documents

Publication Publication Date Title
Richard et al. Pharmaceutical treatment of osteoarthritis
US20080113973A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2
JP2005533830A5 (enExample)
US20100048518A1 (en) Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent
JPH01503539A (ja) 非鎮静抗ヒスタミン薬を含んでなる咳/風邪用混合物
Chamie et al. Peripherally acting μ-opioid receptor antagonists in the management of postoperative ileus: a clinical review
KR101864559B1 (ko) 정맥 내 투여용 이부프로펜의 투여
JPS59112948A (ja) コレステロ−ルレベル低下剤
CA2476939A1 (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
CN102076337A (zh) 决奈达隆的单独或组合在制备用于治疗具有心律失常并具有肌酸酐水平升高的患者的药物中的用途
Seymour Drug interactions in dentistry
JP2008100924A (ja) 総合感冒薬組み合わせ製剤
Jaksch et al. 4 years after withdrawal of rofecoxib: where do we stand today?
JP2010524906A (ja) パーキンソン病に伴う運動不全の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
Goswami et al. Comparative Evaluation of Two Doses of Etoricoxib (90 mg and 120 mg) as Pre-Emptive Analgesic for Post-Operative Pain Relief in Mandibular Fracture Surgery Under General Anaesthesia: A Prospective, Randomised, Double-Blinded, Placebo-Controlled Trial
TWI423800B (zh) 4-環丙基甲氧基-n-(3,5-二氯-1-氧離子基吡啶-4-基)-5-(甲氧基)吡啶-2-甲醯胺於製備用於治療顱部創傷的藥物之用途
US12168000B2 (en) Methods of treating pain
WO2024221023A1 (en) Anti-inflammatory, analgesic and antipyretic suppository
Coyle Guideline For The Administration Of Medicines In The Peri-Operative Period, Version 3
JP2007508242A5 (enExample)
US20100305074A1 (en) Niacin-based pharmaceutical compositions
US20210179623A1 (en) New chemical compound containing active enantiometer s-(-) ketorolac tromethamine for the treatment of pain
Goldberg Non-Statin Treatment of Dyslipidemia
Pain Non-opioid Analgesics
JP2007508242A (ja) トロンボキサンa2受容体アンタゴニストとシクロオキシゲネーゼ−1の阻害剤との組み合わせを伴う組成物および方法